[{"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124-001", "question": "A 34-year-old woman presents with 6 months of progressive bilateral hand weakness and numbness. She has a 15-year history of systemic lupus erythematosus treated with hydroxychloroquine and low-dose prednisone. Examination reveals symmetric weakness of finger abduction and adduction bilaterally, decreased sensation to pinprick over the ulnar aspect of both hands, and absent ulnar deep tendon reflexes. Nerve conduction studies show reduced compound muscle action potential amplitudes in bilateral ulnar nerves with conduction block at the elbow, prolonged distal motor latencies, and temporal dispersion. Anti-ganglioside antibodies are negative. CSF shows protein 85 mg/dL with 2 WBCs. Which of the following is the most likely diagnosis?", "options": ["Multifocal motor neuropathy with conduction block", "Chronic inflammatory demyelinating polyneuropathy", "Lupus-associated mononeuritis multiplex", "Lewis-Sumner syndrome", "Hereditary neuropathy with liability to pressure palsies"], "answer": "D", "answer_index": 3, "explanation": "Lewis-Sumner syndrome (multifocal acquired demyelinating sensory and motor neuropathy, MADSAM) is characterized by asymmetric sensorimotor involvement with demyelinating features including conduction block, distinguishing it from multifocal motor neuropathy (purely motor, anti-GM1 positive) and CIDP (symmetric). The presence of sensory symptoms and signs excludes MMN. Lupus mononeuritis multiplex typically shows axonal rather than demyelinating features. HNPP would show conduction abnormalities at typical compression sites without temporal dispersion.", "generator_model": "claude-opus-4-5-20251101", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: M (Multiple answers defensible). Verdict: Not uniquely determinable. The stem describes bilateral, symmetric ulnar neuropathy with demyelinating features (conduction block, prolonged distal latencies, temporal dispersion) and sensory involvement. Key discriminating findings: bilateral symmetric ulnar nerve involvement, sensory+motor deficits, demyelinating NCS pattern, SLE history, negative anti-ganglioside antibodies, mildly elevated CSF protein. The keyed answer (Lewis-Sumner syndrome/MADSAM) is defined by asymmetric/multifocal sensorimotor neuropathy, but the vignette explicitly describes symmetric bilateral involvement. CIDP (option B) better fits symmetric sensorimotor demyelinating polyneuropathy with elevated CSF protein. The explanation claims asymmetric involvement distinguishes Lewis-Sumner from CIDP, yet the stem states \\\"symmetric weakness\\\" and \\\"bilateral\\\" findings throughout. This creates a fundamental mismatch: if truly symmetric, CIDP is more defensible; if asymmetric/multifocal (as Lewis-Sumner requires), the stem contradicts itself by stating \\\"symmetric.\\\" The item conflates symmetric presentation with a diagnosis requiring asymmetry. Main medical issue: Lewis-Sumner syndrome diagnosis requires multifocal/asymmetric distribution, not the symmetric bilateral pattern described. Minimal fix: Change stem to \\\"asymmetric weakness predominantly affecting ulnar distributions\\\" or change key to B (CIDP) if maintaining symmetric presentation.\", \"medical_accuracy_score\": \"3\", \"logical_validity\": false, \"logical_false_reason\": \"M\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: M (Multiple answers defensible). Verdict: Not uniquely determinable. The stem describes bilateral, symmetric ulnar neuropathy with demyelinating features (conduction block, prolonged distal latencies, temporal dispersion) and sensory involvement. Key discriminating findings: bilateral symmetric ulnar nerve involvement, sensory+motor deficits, demyelinating NCS pattern, SLE history, negative anti-ganglioside antibodies, mildly elevated CSF protein. The keyed answer (Lewis-Sumner syndrome/MADSAM) is defined by asymmetric/multifocal sensorimotor neuropathy, but the vignette explicitly describes symmetric bilateral involvement. CIDP (option B) better fits symmetric sensorimotor demyelinating polyneuropathy with elevated CSF protein. The explanation claims asymmetric involvement distinguishes Lewis-Sumner from CIDP, yet the stem states \"symmetric weakness\" and \"bilateral\" findings throughout. This creates a fundamental mismatch: if truly symmetric, CIDP is more defensible; if asymmetric/multifocal (as Lewis-Sumner requires), the stem contradicts itself by stating \"symmetric.\" The item conflates symmetric presentation with a diagnosis requiring asymmetry. Main medical issue: Lewis-Sumner syndrome diagnosis requires multifocal/asymmetric distribution, not the symmetric bilateral pattern described. Minimal fix: Change stem to \"asymmetric weakness predominantly affecting ulnar distributions\" or change key to B (CIDP) if maintaining symmetric presentation.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124-002", "question": "A 28-year-old woman at 32 weeks gestation presents with sudden onset severe headache, visual disturbances, and confusion. Blood pressure is 178/112 mmHg. Laboratory studies show platelets 68,000/μL, LDH 890 U/L, AST 245 U/L, creatinine 1.8 mg/dL, and peripheral smear with schistocytes. She receives magnesium sulfate and labetalol. Emergent cesarean delivery is performed. Postpartum day 3, despite delivery, her platelet count drops to 42,000/μL, creatinine rises to 2.9 mg/dL, and she develops new neurological symptoms. ADAMTS13 activity returns at 58%. Which additional finding would most strongly support initiating eculizumab therapy?", "options": ["Positive direct antiglobulin test", "Complement factor H mutation on genetic testing", "Elevated soluble fms-like tyrosine kinase-1 levels", "Low C3 with normal C4 levels", "Presence of anti-phospholipid antibodies"], "answer": "B", "answer_index": 1, "explanation": "This presentation of postpartum thrombotic microangiopathy not resolving after delivery with ADAMTS13 >10% suggests complement-mediated TMA (atypical HUS) rather than TTP or HELLP syndrome. Complement factor H mutation confirms complement dysregulation and strongly supports eculizumab (C5 inhibitor) therapy. Low C3 with normal C4 suggests alternative pathway activation but is nonspecific. Elevated sFlt-1 would suggest ongoing preeclampsia-related pathology. Positive DAT would suggest Evans syndrome, and anti-phospholipid antibodies suggest catastrophic APS, both requiring different management.", "generator_model": "claude-opus-4-5-20251101", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The vignette describes a 32-week pregnant woman with severe preeclampsia/HELLP syndrome features (hypertension, thrombocytopenia, elevated LDH/AST, schistocytes, renal dysfunction) who undergoes emergent delivery but worsens postpartum with progressive thrombocytopenia, worsening renal function, and new neurological symptoms. ADAMTS13 activity of 58% (>10%) excludes TTP. The key discriminating finding is postpartum worsening despite delivery, which argues against preeclampsia/HELLP (typically resolves post-delivery) and points toward complement-mediated TMA (atypical HUS). Choice B (complement factor H mutation) directly confirms complement dysregulation and provides the strongest genetic evidence for atypical HUS, making eculizumab (C5 inhibitor) the appropriate therapy. Choice D (low C3, normal C4) suggests alternative pathway activation but is nonspecific and can occur in various conditions. Choice C (elevated sFlt-1) would suggest persistent preeclampsia pathology, not requiring eculizumab. Choices A and E point to different diagnoses (Evans syndrome, catastrophic APS). The stem provides sufficient discriminating features, and the keyed answer is medically sound. Medical accuracy: The clinical reasoning aligns with current understanding of pregnancy-associated TMA and eculizumab indications. Minimal fix: None needed; item is valid.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The vignette describes a 32-week pregnant woman with severe preeclampsia/HELLP syndrome features (hypertension, thrombocytopenia, elevated LDH/AST, schistocytes, renal dysfunction) who undergoes emergent delivery but worsens postpartum with progressive thrombocytopenia, worsening renal function, and new neurological symptoms. ADAMTS13 activity of 58% (>10%) excludes TTP. The key discriminating finding is postpartum worsening despite delivery, which argues against preeclampsia/HELLP (typically resolves post-delivery) and points toward complement-mediated TMA (atypical HUS). Choice B (complement factor H mutation) directly confirms complement dysregulation and provides the strongest genetic evidence for atypical HUS, making eculizumab (C5 inhibitor) the appropriate therapy. Choice D (low C3, normal C4) suggests alternative pathway activation but is nonspecific and can occur in various conditions. Choice C (elevated sFlt-1) would suggest persistent preeclampsia pathology, not requiring eculizumab. Choices A and E point to different diagnoses (Evans syndrome, catastrophic APS). The stem provides sufficient discriminating features, and the keyed answer is medically sound. Medical accuracy: The clinical reasoning aligns with current understanding of pregnancy-associated TMA and eculizumab indications. Minimal fix: None needed; item is valid.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124-003", "question": "A 52-year-old man with hypertrophic cardiomyopathy and an ICD presents with recurrent appropriate shocks for ventricular tachycardia despite maximum tolerated doses of metoprolol and disopyramide. Echocardiogram shows septal thickness of 22 mm, LVOT gradient of 85 mmHg at rest, and moderate mitral regurgitation with systolic anterior motion. Cardiac MRI demonstrates 18% late gadolinium enhancement predominantly in the septum. Coronary angiography is normal. Which intervention is most likely to reduce his arrhythmia burden?", "options": ["Alcohol septal ablation", "Surgical septal myectomy with mitral valve repair", "Catheter ablation of ventricular tachycardia", "Addition of amiodarone to current regimen", "Cardiac transplantation evaluation"], "answer": "B", "answer_index": 1, "explanation": "In HCM patients with significant LVOT obstruction, extensive LGE (>15%), and recurrent VT, surgical myectomy is preferred over alcohol septal ablation because ASA creates additional scar that may be proarrhythmic. Myectomy reduces obstruction and allows concomitant mitral valve repair for SAM-related MR. The extensive LGE indicates high arrhythmic substrate burden. VT ablation addresses the arrhythmia but not the underlying obstruction driving symptoms. Amiodarone adds toxicity risk without addressing mechanism. Transplant is premature given available surgical options.", "generator_model": "claude-opus-4-5-20251101", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The stem describes a 52-year-old man with hypertrophic cardiomyopathy presenting with refractory ventricular tachycardia despite maximal medical therapy (metoprolol + disopyramide). Key discriminating findings include: (1) severe LVOT obstruction (85 mmHg gradient at rest), (2) significant septal hypertrophy (22 mm), (3) moderate MR with SAM, (4) extensive myocardial fibrosis (18% LGE), and (5) recurrent appropriate ICD shocks despite medical therapy. The clinical problem asks which intervention will reduce arrhythmia burden in this complex patient. Option B (surgical myectomy with mitral valve repair) is the best answer because it addresses both the severe LVOT obstruction and the SAM-related MR while avoiding creation of additional arrhythmogenic scar that occurs with alcohol septal ablation. In patients with extensive LGE (>15%), surgical myectomy is preferred over ASA due to lower proarrhythmic risk. Option A is inferior because ASA creates iatrogenic scar in a patient already at high arrhythmic risk. Option C addresses arrhythmia but not the hemodynamic substrate. Option D adds toxicity without addressing mechanism. Option E is premature when definitive surgical therapy is available. The item is medically accurate, logically sound, and supports a unique best answer matching the key. No fix needed.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The stem describes a 52-year-old man with hypertrophic cardiomyopathy presenting with refractory ventricular tachycardia despite maximal medical therapy (metoprolol + disopyramide). Key discriminating findings include: (1) severe LVOT obstruction (85 mmHg gradient at rest), (2) significant septal hypertrophy (22 mm), (3) moderate MR with SAM, (4) extensive myocardial fibrosis (18% LGE), and (5) recurrent appropriate ICD shocks despite medical therapy. The clinical problem asks which intervention will reduce arrhythmia burden in this complex patient. Option B (surgical myectomy with mitral valve repair) is the best answer because it addresses both the severe LVOT obstruction and the SAM-related MR while avoiding creation of additional arrhythmogenic scar that occurs with alcohol septal ablation. In patients with extensive LGE (>15%), surgical myectomy is preferred over ASA due to lower proarrhythmic risk. Option A is inferior because ASA creates iatrogenic scar in a patient already at high arrhythmic risk. Option C addresses arrhythmia but not the hemodynamic substrate. Option D adds toxicity without addressing mechanism. Option E is premature when definitive surgical therapy is available. The item is medically accurate, logically sound, and supports a unique best answer matching the key. No fix needed.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124-004", "question": "A 45-year-old woman with dermatomyositis diagnosed 8 months ago presents with progressive dyspnea. She was initially treated with high-dose prednisone and azathioprine with improvement in proximal muscle weakness. CT chest shows new ground-glass opacities with peripheral consolidation in lower lobes. Pulmonary function tests reveal FVC 58% predicted, DLCO 42% predicted. Bronchoalveolar lavage shows 35% lymphocytes. She tests positive for anti-MDA5 antibodies. Which treatment approach offers the best chance of halting disease progression?", "options": ["Increase prednisone and add mycophenolate mofetil", "Triple therapy with high-dose glucocorticoids, calcineurin inhibitor, and cyclophosphamide", "Rituximab with continued azathioprine", "Nintedanib with continued current immunosuppression", "Plasma exchange followed by IVIG maintenance"], "answer": "B", "answer_index": 1, "explanation": "Anti-MDA5 dermatomyositis-associated rapidly progressive interstitial lung disease carries high mortality and requires aggressive upfront combination immunosuppression. Japanese and international experience supports triple therapy with high-dose corticosteroids, a calcineurin inhibitor (tacrolimus or cyclosporine), and cyclophosphamide as the most effective approach for halting progression. Single-agent additions or rituximab have shown inferior outcomes in this specific antibody subset. Nintedanib is antifibrotic, not immunosuppressive. Plasma exchange lacks evidence in this context.", "generator_model": "claude-opus-4-5-20251101", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The stem describes a 45-year-old woman with dermatomyositis who develops rapidly progressive interstitial lung disease (RP-ILD) despite initial immunosuppression, with CT showing ground-glass opacities, restrictive physiology (FVC 58%, DLCO 42%), and critically, positive anti-MDA5 antibodies. Anti-MDA5-positive dermatomyositis-associated RP-ILD is a well-characterized, high-mortality syndrome requiring aggressive upfront combination immunosuppression. Key discriminating findings: progressive dyspnea despite treatment, new ILD on imaging, severely reduced DLCO, and anti-MDA5 positivity. Option B (triple therapy with high-dose glucocorticoids, calcineurin inhibitor, and cyclophosphamide) aligns with published Japanese and international protocols showing superior outcomes in anti-MDA5 RP-ILD. Option A (adding mycophenolate) represents inadequate escalation for this aggressive phenotype. Option C (rituximab) lacks robust evidence in anti-MDA5 RP-ILD. Option D (nintedanib) is antifibrotic, not immunosuppressive, inappropriate for acute inflammatory ILD. Option E (plasma exchange/IVIG) lacks evidence in this context. The item is medically accurate, reflecting current understanding that anti-MDA5 RP-ILD requires maximal upfront immunosuppression rather than sequential escalation. Minimal fix: None needed; item is valid and accurate.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The stem describes a 45-year-old woman with dermatomyositis who develops rapidly progressive interstitial lung disease (RP-ILD) despite initial immunosuppression, with CT showing ground-glass opacities, restrictive physiology (FVC 58%, DLCO 42%), and critically, positive anti-MDA5 antibodies. Anti-MDA5-positive dermatomyositis-associated RP-ILD is a well-characterized, high-mortality syndrome requiring aggressive upfront combination immunosuppression. Key discriminating findings: progressive dyspnea despite treatment, new ILD on imaging, severely reduced DLCO, and anti-MDA5 positivity. Option B (triple therapy with high-dose glucocorticoids, calcineurin inhibitor, and cyclophosphamide) aligns with published Japanese and international protocols showing superior outcomes in anti-MDA5 RP-ILD. Option A (adding mycophenolate) represents inadequate escalation for this aggressive phenotype. Option C (rituximab) lacks robust evidence in anti-MDA5 RP-ILD. Option D (nintedanib) is antifibrotic, not immunosuppressive, inappropriate for acute inflammatory ILD. Option E (plasma exchange/IVIG) lacks evidence in this context. The item is medically accurate, reflecting current understanding that anti-MDA5 RP-ILD requires maximal upfront immunosuppression rather than sequential escalation. Minimal fix: None needed; item is valid and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124-005", "question": "A 38-year-old man from Cambodia presents with 3 weeks of fever, headache, and altered mental status. CSF analysis shows opening pressure 32 cm H2O, WBC 180/μL (90% lymphocytes), protein 120 mg/dL, glucose 28 mg/dL (serum 110 mg/dL). India ink preparation shows encapsulated yeast. Cryptococcal antigen titer is 1:2048 in CSF. HIV testing is positive with CD4 count of 35 cells/μL. He is started on liposomal amphotericin B and flucytosine with daily therapeutic lumbar punctures. On day 10, repeat lumbar puncture shows opening pressure 38 cm H2O, CSF WBC 420/μL (85% lymphocytes), protein 180 mg/dL, and cryptococcal antigen titer 1:1024. He has worsening headache and new sixth nerve palsy. What is the most appropriate next step?", "options": ["Add dexamethasone for paradoxical immune reconstitution inflammatory syndrome", "Switch to high-dose fluconazole for amphotericin resistance", "Place a ventriculoperitoneal shunt for refractory elevated intracranial pressure", "Continue current antifungal therapy with more aggressive CSF drainage", "Initiate antiretroviral therapy immediately to improve immune function"], "answer": "D", "answer_index": 3, "explanation": "The rising CSF pleocytosis with persistent elevated opening pressure despite treatment represents ongoing cryptococcal meningitis with inadequate pressure management rather than treatment failure or IRIS (patient not yet on ART). The antigen titer is decreasing appropriately. Management requires more aggressive CSF drainage-either more frequent LPs or temporary lumbar drain placement. Corticosteroids are contraindicated in cryptococcal meningitis (increased mortality in COAT trial). VPS is reserved for truly refractory cases after optimizing medical management. Early ART initiation increases IRIS risk and mortality when started before 4-6 weeks of antifungal therapy.", "generator_model": "claude-opus-4-5-20251101", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The stem describes HIV-associated cryptococcal meningitis with persistently elevated intracranial pressure (ICP) despite daily therapeutic LPs. Key discriminating findings: (1) opening pressure increased from 32→38 cm H2O despite daily LPs, (2) decreasing cryptococcal antigen titer (1:2048→1:1024) indicating antifungal efficacy, (3) rising CSF pleocytosis (180→420 WBC/μL), (4) new sixth nerve palsy indicating worsening ICP, (5) patient not yet on ART (excludes IRIS). The clinical problem is refractory elevated ICP in cryptococcal meningitis with adequate antifungal response. Option D is correct: more aggressive CSF drainage (increased LP frequency or temporary lumbar drain) is standard management for persistent elevated ICP. Option A is wrong: corticosteroids contraindicated in active cryptococcal meningitis (COAT trial showed increased mortality); IRIS unlikely without ART. Option B is wrong: decreasing antigen titer demonstrates antifungal efficacy, not resistance. Option C is premature: VPS reserved for truly refractory cases after optimizing medical drainage. Option E is wrong: early ART (<4-6 weeks) increases IRIS risk and mortality in cryptococcal meningitis. Medical accuracy is excellent; management aligns with current guidelines. Minimal fix: none needed.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The stem describes HIV-associated cryptococcal meningitis with persistently elevated intracranial pressure (ICP) despite daily therapeutic LPs. Key discriminating findings: (1) opening pressure increased from 32→38 cm H2O despite daily LPs, (2) decreasing cryptococcal antigen titer (1:2048→1:1024) indicating antifungal efficacy, (3) rising CSF pleocytosis (180→420 WBC/μL), (4) new sixth nerve palsy indicating worsening ICP, (5) patient not yet on ART (excludes IRIS). The clinical problem is refractory elevated ICP in cryptococcal meningitis with adequate antifungal response. Option D is correct: more aggressive CSF drainage (increased LP frequency or temporary lumbar drain) is standard management for persistent elevated ICP. Option A is wrong: corticosteroids contraindicated in active cryptococcal meningitis (COAT trial showed increased mortality); IRIS unlikely without ART. Option B is wrong: decreasing antigen titer demonstrates antifungal efficacy, not resistance. Option C is premature: VPS reserved for truly refractory cases after optimizing medical drainage. Option E is wrong: early ART (<4-6 weeks) increases IRIS risk and mortality in cryptococcal meningitis. Medical accuracy is excellent; management aligns with current guidelines. Minimal fix: none needed.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124-006", "question": "A 67-year-old woman with longstanding rheumatoid arthritis on methotrexate and adalimumab develops progressive cognitive decline over 4 months. MRI brain shows multifocal white matter lesions without enhancement or mass effect. CSF shows 8 WBCs (all lymphocytes), protein 62 mg/dL, and negative routine cultures. JC virus PCR in CSF is positive with 850 copies/mL. Adalimumab is discontinued. Three weeks later, she develops new right hemiparesis and worsening confusion. Repeat MRI shows enlargement of lesions with new peripheral enhancement and edema. CSF now shows 45 WBCs (predominantly lymphocytes). What is the most appropriate management?", "options": ["Restart adalimumab to suppress destructive inflammation", "Initiate high-dose corticosteroids", "Begin cidofovir and cytarabine combination therapy", "Administer pembrolizumab to enhance JC virus clearance", "Perform brain biopsy to exclude CNS lymphoma"], "answer": "B", "answer_index": 1, "explanation": "This patient has developed immune reconstitution inflammatory syndrome (IRIS) following discontinuation of immunosuppression in the setting of PML. The new enhancement, edema, and increased CSF pleocytosis after stopping adalimumab are classic for PML-IRIS. High-dose corticosteroids are indicated to reduce the inflammatory response that, while representing immune recovery, can cause significant neurological damage. Restarting immunosuppression would be counterproductive. Cidofovir/cytarabine lack efficacy in PML. Pembrolizumab is used in refractory PML without immune reconstitution, not IRIS. Biopsy is unnecessary given confirmed JC virus and classic IRIS presentation.", "generator_model": "claude-opus-4-5-20251101", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The vignette describes a classic PML-IRIS scenario: (1) immunosuppressed patient (methotrexate+adalimumab) develops PML (progressive cognitive decline, multifocal white matter lesions, positive JC virus PCR 850 copies/mL); (2) after stopping adalimumab, develops new deficits with MRI showing enhancement/edema and increased CSF pleocytosis—hallmarks of immune reconstitution inflammatory syndrome. Key discriminating findings: timing (3 weeks post-immunosuppression withdrawal), new enhancement on previously non-enhancing lesions, increased CSF WBCs, clinical worsening paradoxically after stopping the causative agent. The keyed answer (B: high-dose corticosteroids) is the established management for PML-IRIS to dampen excessive inflammatory response while allowing some immune recovery. Alternative analysis: (A) restarting adalimumab contradicts IRIS management principles; (C) cidofovir/cytarabine lack proven PML efficacy; (D) pembrolizumab is experimental for non-IRIS PML, contraindicated in active IRIS; (E) biopsy unnecessary with confirmed JC virus and classic IRIS presentation. Medical accuracy: fully consistent with current PML-IRIS management guidelines. No logical flaws; stem provides sufficient detail for unique best answer. Minimal fix: none needed—item is valid and accurate.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The vignette describes a classic PML-IRIS scenario: (1) immunosuppressed patient (methotrexate+adalimumab) develops PML (progressive cognitive decline, multifocal white matter lesions, positive JC virus PCR 850 copies/mL); (2) after stopping adalimumab, develops new deficits with MRI showing enhancement/edema and increased CSF pleocytosis—hallmarks of immune reconstitution inflammatory syndrome. Key discriminating findings: timing (3 weeks post-immunosuppression withdrawal), new enhancement on previously non-enhancing lesions, increased CSF WBCs, clinical worsening paradoxically after stopping the causative agent. The keyed answer (B: high-dose corticosteroids) is the established management for PML-IRIS to dampen excessive inflammatory response while allowing some immune recovery. Alternative analysis: (A) restarting adalimumab contradicts IRIS management principles; (C) cidofovir/cytarabine lack proven PML efficacy; (D) pembrolizumab is experimental for non-IRIS PML, contraindicated in active IRIS; (E) biopsy unnecessary with confirmed JC virus and classic IRIS presentation. Medical accuracy: fully consistent with current PML-IRIS management guidelines. No logical flaws; stem provides sufficient detail for unique best answer. Minimal fix: none needed—item is valid and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124-007", "question": "A 29-year-old woman presents with 2 years of recurrent oral ulcers, genital ulcers, and bilateral anterior uveitis. She now develops sudden painless vision loss in her right eye. Examination reveals visual acuity of hand motion OD and 20/25 OS. Fundoscopy of the right eye shows diffuse retinal whitening with cherry-red spot and box-carring in retinal arterioles. Fluorescein angiography confirms central retinal artery occlusion. HLA-B51 is positive. Pathergy test is negative. What is the most appropriate immediate intervention to prevent contralateral involvement?", "options": ["High-dose intravenous methylprednisolone alone", "Infliximab infusion", "Combination of high-dose corticosteroids with cyclosporine", "Combination of high-dose corticosteroids with infliximab or adalimumab", "Anterior chamber paracentesis with ocular massage"], "answer": "D", "answer_index": 3, "explanation": "This patient has Behçet disease with ocular involvement including the devastating complication of retinal artery occlusion from retinal vasculitis. Immediate aggressive immunosuppression is critical to prevent bilateral blindness. Current evidence supports combination therapy with high-dose corticosteroids plus a TNF-alpha inhibitor (infliximab or adalimumab) as the most effective approach for severe ocular Behçet. Corticosteroids alone or with cyclosporine are insufficient for this severity. Anterior chamber paracentesis addresses embolic CRAO, not inflammatory vasculitic occlusion. The goal is preventing contralateral involvement through rapid inflammation control.", "generator_model": "claude-opus-4-5-20251101", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: U (Underspecified) leading to M (Multiple answers defensible). Verdict: Not uniquely determinable. The vignette describes Behçet disease with severe ocular involvement (retinal artery occlusion from vasculitis). Key stem clues: recurrent oral/genital ulcers, bilateral anterior uveitis, HLA-B51+, pathergy-negative, and acute CRAO with retinal vasculitis. The question asks for \\\"most appropriate immediate intervention to prevent contralateral involvement.\\\" The keyed answer (D: corticosteroids + TNF-alpha inhibitor) represents aggressive combination therapy. However, the stem is underspecified regarding: (1) whether the patient has already been on any immunosuppression, (2) the exact timing window for \\\"immediate\\\" intervention, and (3) institutional protocols for severe ocular Behçet. While TNF-alpha inhibitors are increasingly favored for severe ocular Behçet, option C (corticosteroids + cyclosporine) has substantial historical support and remains used in many centers. The rationale dismisses cyclosporine as \\\"insufficient\\\" without citing specific evidence that makes TNF-alpha inhibitors definitively superior in this exact scenario. Both C and D represent aggressive combination immunosuppression; the choice between them requires assumptions about comparative efficacy data not established in the stem. Medical accuracy: The pathophysiology and diagnosis are sound (score 4), but the treatment hierarchy lacks definitive consensus. Minimal fix: Add \\\"per current EULAR guidelines\\\" or specify failed prior therapy to justify TNF-alpha inhibitor preference.\",\"medical_accuracy_score\":\"4\",\"logical_validity\":false,\"logical_false_reason\":\"U\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: U (Underspecified) leading to M (Multiple answers defensible). Verdict: Not uniquely determinable. The vignette describes Behçet disease with severe ocular involvement (retinal artery occlusion from vasculitis). Key stem clues: recurrent oral/genital ulcers, bilateral anterior uveitis, HLA-B51+, pathergy-negative, and acute CRAO with retinal vasculitis. The question asks for \"most appropriate immediate intervention to prevent contralateral involvement.\" The keyed answer (D: corticosteroids + TNF-alpha inhibitor) represents aggressive combination therapy. However, the stem is underspecified regarding: (1) whether the patient has already been on any immunosuppression, (2) the exact timing window for \"immediate\" intervention, and (3) institutional protocols for severe ocular Behçet. While TNF-alpha inhibitors are increasingly favored for severe ocular Behçet, option C (corticosteroids + cyclosporine) has substantial historical support and remains used in many centers. The rationale dismisses cyclosporine as \"insufficient\" without citing specific evidence that makes TNF-alpha inhibitors definitively superior in this exact scenario. Both C and D represent aggressive combination immunosuppression; the choice between them requires assumptions about comparative efficacy data not established in the stem. Medical accuracy: The pathophysiology and diagnosis are sound (score 4), but the treatment hierarchy lacks definitive consensus. Minimal fix: Add \"per current EULAR guidelines\" or specify failed prior therapy to justify TNF-alpha inhibitor preference.", "medical_accuracy_score": 4, "logical_validity": false, "logical_false_reason": "U", "verdict": "FAIL", "fail_reason": "U"}, "judge_verdict": "FAIL", "judge_fail_reason": "U", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124-008", "question": "A 41-year-old man with no significant medical history presents with 6 weeks of progressive bilateral lower extremity weakness and paresthesias. He reports a diarrheal illness 8 weeks ago. Examination shows 3/5 strength in hip flexors, 4/5 in knee extensors, 4-/5 in ankle dorsiflexors bilaterally, absent deep tendon reflexes, and decreased vibration sense to the knees. Nerve conduction studies show reduced CMAP amplitudes with normal conduction velocities and no conduction block. Needle EMG shows active denervation in distal leg muscles. CSF protein is 95 mg/dL with 1 WBC. Anti-GM1 IgG antibodies are strongly positive. Despite 5 days of IVIG, he continues to worsen with new respiratory compromise requiring intubation. What is the next best step in management?", "options": ["Repeat IVIG course immediately", "Initiate plasma exchange", "Add high-dose intravenous methylprednisolone", "Begin eculizumab therapy", "Administer second IVIG course after 4-week interval"], "answer": "B", "answer_index": 1, "explanation": "This patient has acute motor axonal neuropathy (AMAN) variant of Guillain-Barré syndrome, evidenced by pure motor axonal pattern on NCS, anti-GM1 antibodies, and preceding Campylobacter-like illness. When patients fail to respond to initial IVIG and continue deteriorating, plasma exchange is the appropriate next step as it works through a different mechanism (antibody removal vs. immunomodulation). The treatments are not synergistic when given together but can be used sequentially. Corticosteroids are ineffective in GBS. Eculizumab has shown promise in refractory cases but is not yet standard of care. Waiting 4 weeks for repeat IVIG is inappropriate in a deteriorating patient.", "generator_model": "claude-opus-4-5-20251101", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The vignette describes a 41-year-old man with classic acute motor axonal neuropathy (AMAN) variant of Guillain-Barré syndrome: preceding diarrheal illness (suggesting Campylobacter), progressive ascending weakness, areflexia, albuminocytologic dissociation (elevated CSF protein, normal WBC), reduced CMAP amplitudes with normal velocities (axonal pattern), active denervation on EMG, and strongly positive anti-GM1 IgG antibodies. The critical discriminating finding is failure to respond to initial IVIG with continued deterioration requiring intubation. Key stem clues: IVIG failure, ongoing progression, respiratory compromise. Plasma exchange (B) is the established next step when first-line IVIG fails in GBS, working through antibody removal rather than immunomodulation. Option A (immediate repeat IVIG) lacks evidence for benefit and delays effective therapy. Option C (corticosteroids) is contraindicated—steroids are ineffective or harmful in GBS. Option D (eculizumab) is investigational, not standard care. Option E (waiting 4 weeks) is dangerous in a deteriorating patient requiring mechanical ventilation. No logical flaws: stem provides sufficient detail, one defensible best answer exists, and the key matches it. Medical accuracy is excellent—management aligns with current GBS guidelines. Minimal fix: None needed; item is valid as written.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The vignette describes a 41-year-old man with classic acute motor axonal neuropathy (AMAN) variant of Guillain-Barré syndrome: preceding diarrheal illness (suggesting Campylobacter), progressive ascending weakness, areflexia, albuminocytologic dissociation (elevated CSF protein, normal WBC), reduced CMAP amplitudes with normal velocities (axonal pattern), active denervation on EMG, and strongly positive anti-GM1 IgG antibodies. The critical discriminating finding is failure to respond to initial IVIG with continued deterioration requiring intubation. Key stem clues: IVIG failure, ongoing progression, respiratory compromise. Plasma exchange (B) is the established next step when first-line IVIG fails in GBS, working through antibody removal rather than immunomodulation. Option A (immediate repeat IVIG) lacks evidence for benefit and delays effective therapy. Option C (corticosteroids) is contraindicated—steroids are ineffective or harmful in GBS. Option D (eculizumab) is investigational, not standard care. Option E (waiting 4 weeks) is dangerous in a deteriorating patient requiring mechanical ventilation. No logical flaws: stem provides sufficient detail, one defensible best answer exists, and the key matches it. Medical accuracy is excellent—management aligns with current GBS guidelines. Minimal fix: None needed; item is valid as written.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124-009", "question": "A 55-year-old woman with mechanical mitral valve replacement on warfarin presents with acute onset aphasia and right hemiplegia. Symptoms began 90 minutes ago. CT head shows no hemorrhage. CT angiography reveals left M1 occlusion. INR is 2.8. CT perfusion shows large penumbra with small core infarct (ASPECTS 8). Blood pressure is 165/95 mmHg. What is the most appropriate next step?", "options": ["Administer IV alteplase followed by endovascular thrombectomy", "Proceed directly to endovascular thrombectomy without IV thrombolysis", "Reverse anticoagulation with 4-factor PCC then administer IV alteplase", "Administer idarucizumab followed by IV alteplase", "Medical management only with blood pressure optimization"], "answer": "B", "answer_index": 1, "explanation": "In patients with acute ischemic stroke on therapeutic anticoagulation (INR >1.7), IV thrombolysis is contraindicated due to bleeding risk. However, mechanical thrombectomy is not contraindicated and should be pursued emergently in patients with large vessel occlusion and favorable perfusion imaging (large penumbra, small core). Reversing anticoagulation to give tPA adds delay and the combination increases bleeding risk. Idarucizumab reverses dabigatran, not warfarin. Medical management alone would result in completed large territory infarction given the M1 occlusion. Direct thrombectomy offers the best risk-benefit profile.", "generator_model": "claude-opus-4-5-20251101", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The stem describes a 55-year-old woman with mechanical mitral valve on warfarin presenting within 90 minutes of large vessel occlusion stroke (left M1) with favorable imaging (ASPECTS 8, large penumbra, small core) but therapeutic INR 2.8. Key discriminating findings: (1) INR 2.8 (>1.7) contraindicates IV alteplase per guidelines, (2) large vessel occlusion with favorable perfusion imaging strongly indicates mechanical thrombectomy, (3) time window permits intervention. Option B (direct thrombectomy) is correct: mechanical thrombectomy is NOT contraindicated by therapeutic anticoagulation and offers definitive reperfusion without bleeding risk of thrombolysis. Option A is contraindicated (INR >1.7). Option C adds dangerous delay and bleeding risk. Option D uses wrong reversal agent (idarucizumab is for dabigatran, not warfarin). Option E abandons salvageable tissue. The item correctly reflects current stroke guidelines distinguishing thrombolysis contraindications from thrombectomy indications. Medical accuracy is excellent. No logical flaws exist. Minimal fix: None needed; item is valid and accurate as written.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The stem describes a 55-year-old woman with mechanical mitral valve on warfarin presenting within 90 minutes of large vessel occlusion stroke (left M1) with favorable imaging (ASPECTS 8, large penumbra, small core) but therapeutic INR 2.8. Key discriminating findings: (1) INR 2.8 (>1.7) contraindicates IV alteplase per guidelines, (2) large vessel occlusion with favorable perfusion imaging strongly indicates mechanical thrombectomy, (3) time window permits intervention. Option B (direct thrombectomy) is correct: mechanical thrombectomy is NOT contraindicated by therapeutic anticoagulation and offers definitive reperfusion without bleeding risk of thrombolysis. Option A is contraindicated (INR >1.7). Option C adds dangerous delay and bleeding risk. Option D uses wrong reversal agent (idarucizumab is for dabigatran, not warfarin). Option E abandons salvageable tissue. The item correctly reflects current stroke guidelines distinguishing thrombolysis contraindications from thrombectomy indications. Medical accuracy is excellent. No logical flaws exist. Minimal fix: None needed; item is valid and accurate as written.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124-010", "question": "A 33-year-old woman with no prior cardiac history presents with progressive exertional dyspnea over 3 months. She delivered her third child 5 months ago. Echocardiogram shows left ventricular ejection fraction of 25%, LV end-diastolic diameter of 62 mm, moderate functional mitral regurgitation, and no thrombus. BNP is 1,850 pg/mL. She is started on guideline-directed medical therapy including sacubitril-valsartan, carvedilol, spironolactone, and dapagliflozin. Genetic testing reveals a truncating variant in the TTN gene. At 6-month follow-up, LVEF has improved to 40% but remains below normal. Which factor most strongly predicts her likelihood of complete LV recovery?", "options": ["Absence of late gadolinium enhancement on cardiac MRI", "Normalization of BNP levels", "Presence of the TTN truncating variant", "Baseline LVEF above 30%", "Multiparity status"], "answer": "A", "answer_index": 0, "explanation": "In peripartum cardiomyopathy, the absence of late gadolinium enhancement (LGE) on cardiac MRI is the strongest predictor of complete LV recovery, indicating absence of irreversible myocardial fibrosis. TTN truncating variants are actually associated with incomplete recovery and persistent LV dysfunction in PPCM, making option C incorrect. While BNP normalization and higher baseline LVEF are favorable, they are less predictive than LGE status. Multiparity is a risk factor for developing PPCM but does not predict recovery. LGE represents scar that cannot recover regardless of optimal medical therapy.", "generator_model": "claude-opus-4-5-20251101", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The vignette describes a 33-year-old woman with peripartum cardiomyopathy (PPCM) presenting 5 months postpartum with heart failure (LVEF 25%, elevated BNP). Key discriminating findings: recent delivery, new-onset cardiomyopathy, TTN truncating variant, partial response to GDMT (LVEF 25%→40%). The question asks which factor most strongly predicts complete LV recovery. The keyed answer (A: absence of LGE on cardiac MRI) is medically accurate—LGE indicates irreversible myocardial fibrosis/scar, and its absence is the strongest predictor of complete recovery in PPCM across multiple studies. Option B (BNP normalization) correlates with recovery but is less specific than LGE. Option C (TTN variant) is actually associated with worse/incomplete recovery, making it incorrect. Option D (baseline LVEF >30%) is favorable but less predictive than LGE status. Option E (multiparity) is a risk factor for PPCM development, not recovery. The stem provides sufficient detail to identify a unique best answer. No logical contradictions exist. Medical accuracy is high—the teaching point aligns with current PPCM literature and cardiac MRI prognostication. Minimal fix: None needed; item is valid as written.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The vignette describes a 33-year-old woman with peripartum cardiomyopathy (PPCM) presenting 5 months postpartum with heart failure (LVEF 25%, elevated BNP). Key discriminating findings: recent delivery, new-onset cardiomyopathy, TTN truncating variant, partial response to GDMT (LVEF 25%→40%). The question asks which factor most strongly predicts complete LV recovery. The keyed answer (A: absence of LGE on cardiac MRI) is medically accurate—LGE indicates irreversible myocardial fibrosis/scar, and its absence is the strongest predictor of complete recovery in PPCM across multiple studies. Option B (BNP normalization) correlates with recovery but is less specific than LGE. Option C (TTN variant) is actually associated with worse/incomplete recovery, making it incorrect. Option D (baseline LVEF >30%) is favorable but less predictive than LGE status. Option E (multiparity) is a risk factor for PPCM development, not recovery. The stem provides sufficient detail to identify a unique best answer. No logical contradictions exist. Medical accuracy is high—the teaching point aligns with current PPCM literature and cardiac MRI prognostication. Minimal fix: None needed; item is valid as written.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}]